Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2024-02-12 00:00:00 ET · period of report 2024-02-12 · accession 0001725160-24-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-12 | 2024-02-12 | ZNTL | Epperly Melissa B, | CFO | S - Sale | $11.44 | -2,573 | 451.4K | -0.6% | -$29.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-12 | S | D | 2,573 | $11.44 | 451,449 | D | — | — | (F2) The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |